Whitepaper: Handheld analyzers for the screening of pharmaceutical counterfeits
Posted: 1 October 2013 | Thermo Fisher Scientific
Counterfeit and substandard medicines have serious human health and economic costs…
The magnitude of the counterfeit and substandard pharmaceutical problem has recently gained significant public attention due to a number of high profile incidents and greater media focus. The World Health Organization (WHO) estimates that up to 10% of the world’s drugs are substandard or counterfeit and are expected to reach $75B. Even more significantly, it is estimated that 700,000 lives will be lost each year due to counterfeit malaria and tuberculosis drugs alone (International Policy Network, 2009).
This whitepaper is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- Safety reporting in clinical trials: six core considerations for success
- ebook: Twin-screw extrusion for pharmaceutical applications
- Biopharmaceuticals contributing to manufacturing outsourcing trend
- Biologics driving continuous bioprocessing market expansion
- Mycoplasma testing market expected to value nearly $2 million by 2031
